Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06390709 · ClinicalTrials.gov registry record
PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT)
A clinical trial of Rheumatoid Arthritis, sponsored by Scipher Medicine.
- Recruiting
- Registry status
- 1,100
- Enrollment target
- 1
- Study location
NCT06390709: Recruiting study of Rheumatoid Arthritis, sponsored by Scipher Medicine.
NCT06390709 is a study of Rheumatoid Arthritis that is actively recruiting participants, run by Scipher Medicine. The registered enrollment target is 1,100 participants, below the 4,685-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06390709, a study of Rheumatoid Arthritis, is actively recruiting participants, sponsored by Scipher Medicine.
- RECRUITING
- Registry status
- 1,100 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective, multi-center-observational study conducted within the US, collecting patient samples for research and development to train, test, and validate precision medicine classifiers. These molecular signature response classifiers (MSRC) aim to predict response status to JAK, T-cell, and IL-6 inhibitor therapies in patients with rheumatoid arthritis (RA).
Conditions Studied
Interventions
- OTHER Lab Collection Only
Study Locations (1)
California
- Medvin Clinical Research//Amicus Arthritis - Whittier
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2024-04-08 |
| Est. Completion | 2025-12-31 |
What NCT06390709 shows while recruiting
NCT06390709 is an observational study that tracks outcomes without assigning an intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, below the 4,685-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Lab Collection Only is the first listed.
NCT06390709 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06390709 about?
NCT06390709 is a clinical study titled "PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT)". Prospective, multi-center-observational study conducted within the US, collecting patient samples for research and development to train, test, and validate precision medicine classifiers. These molecular signature response classifiers (MSRC) aim to predict response status to JAK, T-cell, and IL-6 in...
What is the current status of trial NCT06390709?
This trial is currently recruiting. The enrollment target is 1,100 participants. The study started on 2024-04-08. Estimated completion is 2025-12-31.
What conditions does trial NCT06390709 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT06390709?
The interventions under investigation include: Lab Collection Only (OTHER).
Who is sponsoring clinical trial NCT06390709?
This trial is sponsored by Scipher Medicine, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06390709 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06390709's enrollment target sits among peer trials
1,100 20th of 197 higher than 178 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rheumatology Diet Study
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
RECRUITING · NA
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Physica System Total Knee Replacement Registry Study
RECRUITING · NA
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI